# Olaparib in PALB2 Advanced Pancreatic Cancer

> **NCT06078787** · PHASE2 · RECRUITING · sponsor: **Azienda Ospedaliero-Universitaria di Modena** · enrollment: 16 (estimated)

## Conditions studied

- Advanced Pancreatic Cancer
- Metastatic Pancreatic Cancer

## Interventions

- **DRUG:** Olaparib 150 MG

## Key facts

- **NCT ID:** NCT06078787
- **Lead sponsor:** Azienda Ospedaliero-Universitaria di Modena
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-01
- **Primary completion:** 2025-08-01
- **Final completion:** 2026-08-01
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2024-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06078787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06078787, "Olaparib in PALB2 Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06078787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*